9YE-15720-66170
4 vaccinations
3 coded responses
19 check-ins
3 free-text entries
1 call case
- Sex
- Male
- Age at first dose
- 41-45
- ZIP prefix
- 626 / IL
- Registered
- 2020-12-20
- Relationship
- Self
- Race
- White
- Ethnicity
- Not Hispanic or Latino
Timeline
-
2020-12-20
Registered in v-safe
-
2020-12-20
Dose 1 — Pfizer-BioNTech
- 2020-12-20
- 2020-12-21
- 2020-12-22
- 2020-12-27
- 2021-01-05
-
2021-01-10
Dose 2 — Pfizer-BioNTech
-
2021-01-11
Health check-in — days 1–6 daily, dose 2Feeling: Poor · Site: Pain, Swelling · Fever · Chills, Headache, Joint pains, Muscle or body aches, Fatigue or tiredness · Be unable to work, Be unable to do your normal daily activitiesAdult check-in
-
2021-01-11
Report sent to call center — days 1–6 daily, dose 2Be unable to work · Be unable to do your normal daily activities1 call case(s)
- 2021-01-15
- 2021-01-16
- 2021-01-17
- 2021-01-24
- 2021-01-31
- 2021-02-07
- 2021-02-14
- 2021-02-23
- 2021-04-11
-
2021-07-11
Survey response — 6 months, dose 2MedDRA: Adverse reaction, Hypersensitivity, Lacrimation increased, Rhinorrhoea, Sneezing — Feeling: FairFree text: Intermittent rhinorrhea, sneezing, watery eyes consistent with allergy type symptoms.MedDRA releases: 2021-09,2023-04,2024-11 · check-in free text available
-
2021-11-19
Dose 3 — Moderna
-
2022-01-10
Survey response — 12 months, dose 2MedDRA: COVID-19, Pharyngitis, Rhinorrhoea, SARS-CoV-2 test positive — Feeling: Good · Be unable to work or attend schoolFree text: Rhinorrhea and pharyngitis related to COVID infection, tested positive 12/29MedDRA releases: 2024-11 · check-in free text available
-
2022-11-19
Survey response — 12 months, dose 3MedDRA: Abdominal discomfort, Constipation, Diarrhoea, Fatigue, Headache, Pre-existing disease, Rhinorrhoea — Feeling: Poor · Be unable to do your normal daily activitiesFree text: starting today, experiencing GI upset, fatigue, loose stool, headache, rhinorrhea. Have had small similar episodes intermittently that last 24 hours or less. Have a history of constipation, mild constipated IBS, this is a change from previous symoMedDRA releases: 2024-11 · check-in free text available
-
2023-01-04
Dose 4 — Other-Unknown
- 2023-04-11
Vaccinations
| Dose | Date | Manufacturer | Co-administered |
|---|---|---|---|
| 1 | 2020-12-20 | Pfizer-BioNTech | |
| 2 | 2021-01-10 | Pfizer-BioNTech | |
| 3 | 2021-11-19 | Moderna | No |
| 4 | 2023-01-04 | Other-Unknown | No |
Call center
1 call center case
1 priority 2/3 (triaged and no follow up)
Free text
Release 9 — 6 months, dose 2
Symptoms: Intermittent rhinorrhea, sneezing, watery eyes consistent with allergy type symptoms.
Release 10 — 12 months, dose 2
Symptoms: Rhinorrhea and pharyngitis related to COVID infection, tested positive 12/29
Release 12 — 12 months, dose 3
Symptoms: starting today, experiencing GI upset, fatigue, loose stool, headache, rhinorrhea. Have had small similar episodes intermittently that last 24 hours or less. Have a history of constipation, mild constipated IBS, this is a change from previous symo cut off by CDC
Each entry is dated by the survey it was written in (the CDC re-sent the releases with survey dates in 2025); click a date to see that survey response. The CDC cut some text off at about 250 characters: symptoms in every release, and the other two fields in releases 9-12. Those entries are marked "cut off by CDC".
MedDRA terms by release
| Field | Preferred term | 2021-09 | 2023-04 | 2024-11 |
|---|---|---|---|---|
| SD | Abdominal discomfort | · | · | ✓ |
| SD | Adverse reaction | · | · | ✓ |
| SD | Constipation | · | · | ✓ |
| SD | COVID-19 | · | · | ✓ |
| SD | Diarrhoea | · | · | ✓ |
| SD | Fatigue | · | · | ✓ |
| SD | Headache | · | · | ✓ |
| SD | Hypersensitivity | ✓ | ✓ | ○ |
| SD | Lacrimation increased | ✓ | ✓ | ✓ |
| SD | Pharyngitis | · | · | ✓ |
| SD | Pre-existing disease | · | · | ✓ |
| SD | Rhinorrhoea | ✓ | ✓ | ✓ |
| SD | SARS-CoV-2 test positive | · | · | ✓ |
| SD | Sneezing | ✓ | ✓ | ✓ |
✓ active code · ○ coded but marked inactive · blank = not in that release